Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06998524 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
A Phase 3 study of Von Willebrand Disease, Type 3, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT06998524 is a Phase 3 study of Von Willebrand Disease, Type 3 that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 75 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06998524, a Phase 3 study of Von Willebrand Disease, Type 3, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be assessed via a randomized comparison (Arm A - emicizumab prophylaxis and Arm B - continuation of SOC on-demand therapy), while participants on prior SOC prophylactic therapy (Arm C - emicizumab prophylaxis) will be assessed via intra-participant analysis with data obtained from the preceding non-interventional study (NIS), WP45335 (NCT06883240).
Conditions Studied
Interventions
- DRUG Emicizumab
- DRUG von Willebrand Factor (VWF) Concentrates
- DRUG Factor VIII (FVIII) Concentrates
- DRUG von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates
- DRUG Bypassing Agents
Study Locations (20)
Other
- UZ Leuven Gasthuisberg - Leuven
- IPS SURA Industriales Medellín - Medellín
- Hopital Claude Huriez - CHU Lille - Lille
- Groupe Hospitalier Necker Enfants Malades - Paris
- Universitätsklinikum Bonn - Bonn
- Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz - Duisburg
- Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin - Frankfurt/M.
- Kurume University Hospital - Fukuoka
- Nagoya University Hospital - Nagoya
- Erasmus MC - Rotterdam
- Instytut Hematologii i Transfuzjologii - Warsaw
California
- UC Davis - Sacramento
Florida
- University of Florida - Gainesville
Minnesota
- University of Minnesota Medical Center - Minneapolis
Missouri
- Washington University School of Medicine - St Louis
Ontario
- The Hospital for Sick Children - Toronto
Quebec
- McGill University Health Center - Montreal
Lazio
- Universita' Degli Studi La Sapienza-Ist.Di Ematologia - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06998524
The ClinicalTrials.gov registry entry for NCT06998524 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Von Willebrand Disease, Type 3 appearing as the primary indexed condition, and to 5 interventions - of which Emicizumab is the first listed.
NCT06998524 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06998524 about?
NCT06998524 is a clinical study titled "A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease". This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior stan...
What is the current status of trial NCT06998524?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2025-06-27. Estimated completion is 2029-03-30.
What conditions does trial NCT06998524 study?
This clinical trial studies the following conditions: Von Willebrand Disease, Type 3.
What interventions are being tested in trial NCT06998524?
The interventions under investigation include: Emicizumab (DRUG), von Willebrand Factor (VWF) Concentrates (DRUG), Factor VIII (FVIII) Concentrates (DRUG), von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates (DRUG), Bypassing Agents (DRUG).
Who is sponsoring clinical trial NCT06998524?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06998524 being conducted?
This trial has 20 study locations across California, Florida, Minnesota, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease, Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.